David Chiswell

David John Chiswell founded MedImmune Ltd. in 1990, where he worked as Chief Executive Officer from 1996 to 2002.
Dr. Chiswell also currently works at Albireo Ltd., as Executive Chairman from 2007, Albireo AB, as Chairman from 2007, Avillion LLP, as Director from 2019, and Bond 2 Development 2 Gp Ltd., as Director.
Dr. Chiswell also formerly worked at Kymab Ltd., as Chief Executive Officer & Director from 2016 to 2019, Arrow Therapeutics Ltd., as Non-Executive Chairman, Sosei Co. Ltd., as Non-Executive Chairman, Nxera Pharma Co., Ltd., as Non-Executive Chairman, Summit (Cambridge) Ltd., as Non-Executive Chairman, The Bioindustry Association, as Chairman, Albireo Pharma, Inc., as Chairman from 2008 to 2023, Epsilogen Ltd., as Non-Executive Chairman from 2019 to 2024, Sosei R&D Ltd., as Director from 2002 to 2013, The Schiehallion Fund Ltd., as Non-Executive Director from 2021 to 2024, The Medical Research Council, as Principal, Phase4 Partners Ltd., as Advisor, the University of California, Los Angeles, as Principal, GE Healthcare Ltd. (United Kingdom), as Principal, Nabriva Therapeutics GmbH, as Member-Supervisory Board from 2012 to 2016, and The Institute of Virology, as Principal.
Dr. Chiswell received his doctorate degree from the University of Glasgow and undergraduate degree from Queen Mary University of London.